D. Boral Capital Reiterates "Buy" Rating for Anixa Biosciences (NASDAQ:ANIX)

Key Points

• Anixa Biosciences' stock has received a "buy" rating from D. Boral Capital, with a price target of $10.00, indicating a potential upside of 235.57% from its previous close.
• Wall Street Zen upgraded Anixa's rating from "sell" to "hold," and three research analysts currently rate the stock as a "buy" with an average price target of $9.00.
• Insider trading activity includes Director Lewis H. Titterton, Jr. acquiring 10,000 shares at $3.08 each, marking a 1.06% increase in ownership, while insiders collectively bought 35,000 shares in the last 90 days.

D. Boral Capital restated their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX - Free Report) in a research report report published on Tuesday,Benzinga reports. The brokerage currently has a $10.00 target price on the stock.

Separately, Wall Street Zen upgraded Anixa Biosciences from a "sell" rating to a "hold" rating in a report on Friday, June 6th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $9.00.

Anixa Biosciences Price Performance

Shares of Anixa Biosciences stock traded down $0.02 during trading hours on Tuesday, hitting $2.93. The company had a trading volume of 102,241 shares, compared to its average volume of 102,823. The company has a market cap of $94.38 million, a P/E ratio of -8.37 and a beta of 0.58. The company's 50-day moving average is $3.11 and its two-hundred day moving average is $2.97. Anixa Biosciences has a twelve month low of $2.07 and a twelve month high of $4.20.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last announced its quarterly earnings data on Wednesday, September 10th. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.03. Sell-side analysts expect that Anixa Biosciences will post -0.41 EPS for the current year.

Insiders Place Their Bets

In other Anixa Biosciences news, Director Lewis H. Titterton, Jr. bought 10,000 shares of the stock in a transaction on Thursday, July 31st. The stock was purchased at an average price of $3.08 per share, for a total transaction of $30,800.00. Following the completion of the purchase, the director directly owned 953,334 shares in the company, valued at approximately $2,936,268.72. This trade represents a 1.06% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have acquired a total of 35,000 shares of company stock worth $110,700 in the last three months. 25.30% of the stock is owned by insiders.

Institutional Trading of Anixa Biosciences

Several institutional investors have recently added to or reduced their stakes in ANIX. Benjamin Edwards Inc. acquired a new position in shares of Anixa Biosciences during the second quarter valued at $37,000. Jane Street Group LLC lifted its holdings in Anixa Biosciences by 37.2% in the 2nd quarter. Jane Street Group LLC now owns 41,800 shares of the company's stock valued at $138,000 after acquiring an additional 11,340 shares during the last quarter. NewEdge Advisors LLC acquired a new stake in Anixa Biosciences in the 2nd quarter valued at about $33,000. Marshall Wace LLP acquired a new stake in Anixa Biosciences in the 2nd quarter valued at about $39,000. Finally, Private Advisor Group LLC acquired a new stake in Anixa Biosciences in the 1st quarter valued at about $35,000. Institutional investors own 29.13% of the company's stock.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.